CB1 Medical
CB1 Medical is a Leicester, UK-based medical entity founded in 2023 with 9 employees. Its specific products, technology, and customer base are unverifiable from current sources, as the public website displays a non-functional loading page.
- Company typePrivate
- Founded-
- Headquarters—
- Headcount1–10
- GTM typeB2C
- OfferingServices
What CB1 Medical does
CB1 Medical is a United Kingdom-based medical entity incorporated in 2023 and headquartered in Leicester, operating with a 9-person team. The brand name references the CB1 cannabinoid receptor, suggesting thematic alignment with cannabinoid or endocannabinoid-system-related medical activity, though the specific therapeutic focus, product portfolio, and clinical pipeline cannot be confirmed from available sources.
At the time of data capture, the company's public website (cb1medical.com) was presenting a loading/verification interstitial rather than substantive company content. As a result, no products, services, underlying technology, clinical assets, regulatory filings, certifications, partnerships, customer segments, pricing structure, distribution channels, or revenue model could be verified. The input also lacks disclosed funding rounds, management team details, office locations beyond the Leicester headquarters, social profiles, patents, trademarks, or M&A history.
On that evidentiary basis, CB1 Medical should be regarded as an early-stage, sub-scale UK medical entity whose commercial direction, technological stack, and go-to-market mechanics are presently unobservable. Any further diligence — including confirmation of whether the company operates in cannabinoid therapeutics, medical devices, digital health, or a related vertical — requires primary-source verification beyond what the current loading-state website and empty data fields provide.
CB1 Medical firmographics
Firmographics- Name
- CB1 Medical
- Website
- https://cb1medical.com
- Company type
- Private
- Headcount range
- 1–10 employees
- Short description
- CB1 Medical is a Leicester, UK-based medical entity founded in 2023 with 9 employees. Its specific products, technology, and customer base are unverifiable from current sources, as the public website displays a non-functional loading page.
- Ownership category
- akta.pro rank
CB1 Medical business model
Business model- GTM type
- B2C
- Offering type
- Services
CB1 Medical product offering
Product offeringCore offering
No core offering could be determined from the available source material. The CB1 Medical website (cb1medical.com) only displays a loading/verification page and contains no product, service, or business description.
Differentiator
Problem solved
Functional benefit
Companies that use CB1 Medical
Customer profileIdeal customer profiles1 record
CB1 Medical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
CB1 Medical partnerships and signals
Strategic signalRecent moves1 record
CB1 Medical competitors and assessment
Company assessmentDirect peers
- Aelis Farma: Clinical-stage French biotech specifically developing CB1 receptor signaling-specific compounds (CB1-SSi) for metabolic and neurological disorders. The most directly comparable peer in terms of both target (CB1) and indication strategy.
- Corbus Pharmaceuticals: US-based biotech developing endocannabinoid system-targeted therapeutics, historically focused on cannabinoid receptor pathways. Comparable as a small-cap, endocannabinoid-focused drug developer.
Emerging players
- Artelo Biosciences: Clinical-stage biotech developing cannabinoid receptor-modulating therapeutics for cancer, pain, and inflammation. Comparable as a small, endocannabinoid-pathway-focused developer.
- Botanix Pharmaceuticals: Clinical-stage dermatology-focused cannabinoid therapeutics company developing synthetic CBD formulations (e.g., Sofpironium Bromide). Comparable as a small-cap cannabinoid therapeutics developer pursuing differentiated formulations.
- Ananda Developments: UK-listed, early-stage company developing cannabinoid-based medicines for chronic conditions including endometriosis and epilepsy. Comparable as a UK-based, early-stage cannabinoid therapeutics developer.
- InMed Pharmaceuticals: Pre-clinical/early-clinical stage cannabinoid pharmaceutical company focused on rare cannabinoid APIs and formulation technology. Comparable as a small-cap cannabinoid-based therapeutic developer.
Broad incumbents
- Jazz Pharmaceuticals (GW Pharmaceuticals): Acquired GW Pharmaceuticals in 2021 and now markets Epidiolex (cannabidiol) and previously Sativex — the established incumbent in cannabinoid-based prescription medicines. Comparable as a benchmark for the regulatory and commercial path of cannabinoid therapeutics.
- Tilray Brands: Large diversified cannabis company with a pharmaceutical division working on cannabinoid-based medicines. Provides a broader industry benchmark rather than a direct preclinical R&D competitor.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat1 record
Key risks4 records
Key highlights2 records
Customer concentration
CB1 Medical social profiles
Digital presenceCB1 Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
CB1 Medical leadership team
Management profileNumber of profiles
CB1 Medical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CB1 Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CB1 Medical
What does CB1 Medical do?
No core offering could be determined from the available source material. The CB1 Medical website (cb1medical.com) only displays a loading/verification page and contains no product, service, or business description.
When was CB1 Medical founded?
CB1 Medical was founded in -1. It employs 1 to 10 people.
Who are CB1 Medical's main competitors?
Direct peers on record are Aelis Farma and Corbus Pharmaceuticals. Emerging players are Artelo Biosciences, Botanix Pharmaceuticals, Ananda Developments and InMed Pharmaceuticals. Broad incumbents are Jazz Pharmaceuticals (GW Pharmaceuticals) and Tilray Brands.
Does CB1 Medical have an API?
No public API is recorded for CB1 Medical.